CTLA4 and arthritic joint disease: In clinical patients, although irAE such as arthritis and pneumonitis may occur with monotherapy, in animal model studies, anti-CTLA4 or anti-PD1 monotherapy cannot induce significant arthritis and pneumonitis, and the combination of the both is used to mimic the clinical manifestations (23).